American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer — JOP

* Copyright © 2010 by American Society of Clinical Oncology

American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

1. Harold J. Burstein, MD, PhD,
2. Jennifer J. Griggs, MD, MPH,
3. Ann A. Prestrud, MPH and
4. Sarah Temin, MSPH

+ Author Affiliations

1.
Dana-Farber Cancer Institute, Boston, MA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; American Society of Clinical Oncology, Alexandria, VA

1. Corresponding author: Sarah Temin, MSPH, American Society of Clinical Oncology, 2318 Mill Rd, Ste 800, Alexandria, VA 22314; e-mail: sarah.temin@asco.org.

Introduction

Journal of Clinical Oncology recently published the ASCO clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer.1 ASCO initially published its first technology assessment of the use of aromatase inhibitors (AIs) in the adjuvant setting in 2002; it was last updated in 2004. ASCO's Update Committee on Aromatase Inhibitors reconvened in May 2009 to update this guideline.

In its current update, the Committee considered various adjuvant endocrine strategies, including tamoxifen, AIs, or both in sequence; the appropriate duration of AI therapy; the long-term adverse effects of AI therapy; identification of subpopulations that might …
American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer — JOP